Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EpCAM CAR-T in advanced gastric cancer
NCT03563326Phase 1Unknown
- Start
- Aug 2018
- Primary completion
- Dec 2019
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of EpCAM CAR-T in gastric cancer (GC) (2 arms). Primary endpoint: Adverse Events at 4 weeks. Status: unknown.
02
Drugs
EpCAM CAR-T
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT03563326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03563326.